Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
68,079.61 +971.04 (+1.45%) CMC Crypto 200
1,377.83 +47.22 (+3.55%)
Valerio Therapeutics Société anonyme (C4X.F)
| Previous close | 0.0974 |
| Open | 0.0883 |
| Bid | 0.0979 x 460000 |
| Ask | 0.0997 x 450000 |
| Day's range | 0.0883 - 0.0883 |
| 52-week range | 0.0840 - 0.3320 |
| Volume | |
| Avg. volume | 149 |
| Market cap | 13.723M |
| Beta (5Y monthly) | 1.70 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1500 |
| Earnings date | 25 Sept 2024 - 09 Oct 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireValerio Therapeutics: Report on the Combined General Meeting of June 4, 2024
PARIS, June 05, 2024--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced that the Combined (Ordinary and Extraordinary) General Meeting held today at 2 pm was able to validly deliberate with a quorum of 48.1%.
Business WireValerio Therapeutics Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial
PARIS, May 22, 2024--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced the completion of dosing for the first cohort of subjects in its Phase 1/2 trial of lead candidate, VIO-01, a pan-DDR decoy for the treatment of solid tumors.
Business WireValerio Therapeutics Reports Full Year 2023 Financial Results and Provides Clinical Development Updates
PARIS, April 30, 2024--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), hereafter "Valerio Therapeutics" or the "Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today reported its consolidated results for the fiscal year ending December 31, 2023.
